Ledger.Open graph →
SEC Form D · Amendment · filed June 16, 2022

Abata Therapeutics, Inc

Offering
$95.0M
Sold
$45.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (26)

Stephen Sofen · CAMBRIDGE, MAExecChristian Villela Klotz · Miami, FLExecJohn Trzupek · CAMBRIDGE, MAExecNagesh Mahanthappa · Cambridge, MADirectorRichard Ronald · San Francisco, CADirectorAbbie Celniker · CAMBRIDGE, MADirectorShelley Chu · CAMBRIDGE, MADirectorExpedition Fund III GP LP · Dallas, TXDirectorRick Smith · Cardiff-by-the-Sea, CADirectorMitch Finer · CAMBRIDGE, MADirectorRobert F. Garland · GREENWOOD VILLAGE, COExec · DirectorValerie Odegard · CAMBRIDGE, MADirectorSandy Lazzari · CAMBRIDGE, MAExecLorence Kim · CAMBRIDGE, MADirectorValerie Odegard · CAMBRIDGE, MADirectorSamantha Singer · CAMBRIDGE, MAExec · DirectorC & C Development Co., LLC · Tustin, CAExecJoshua Clemente · New York, NYDirectorStephen Sofen · CAMBRIDGE, MAExecD. S. Ruegg · San Francisco, CADirectorBruce R. Winson · Dallas, TXDirectorAllen Wolff · Cardiff-by-the-Sea, CADirectorBrian Hirsch · Cardiff-by-the-Sea, CADirectorLadell Robbins · New York, NYExec · DirectorSandy Lazzari · CAMBRIDGE, MAExecNagesh Mahanthappa · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗